Raynaud’s and Systemic Sclerosis

Apricus Biosciences Files for Orphan Drug Designation for RayVa(TM)

Drug Intended for the Treatment of Raynaud’s Phenomena, Secondary to Systemic Sclerosis   SAN DIEGO, April 13, 2011 (GLOBE NEWSWIRE) — Apricus Biosciences, Inc. (“Apricus Bio”) (Nasdaq:APRI) announced today its filing with the U.S. Food & Drug Administration (“FDA”) requesting […]